Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 178
- Registration Number
- NCT05945927
- Locations
- 🇨🇳
Union Hospital of Tongji Medical College, Dept. of Cancer Center, Wuhan, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou City, China
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 72
- Registration Number
- NCT05924243
- Locations
- 🇳🇱
Brain Research Center B.V, Amsterdam, Netherlands
🇳🇱UMC St Radboud, Nijmegen, Netherlands
🇳🇱Brain Research Center Zwolle, Zwolle, Netherlands
RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT05910528
- Locations
- 🇺🇸
Digestive Health Specialists, Dothan, Alabama, United States
🇺🇸Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States
🇺🇸I.H.S Health Northwell Health, Kissimmee, Florida, United States
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT05908786
- Locations
- 🇫🇷
Centre Eugene Marquis (CEM), Rennes, France
🇫🇷Gustave Roussy, Villejuif CEDEX, France
🇩🇪University Essen, Essen, Germany
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 650
- Registration Number
- NCT05904886
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸UCSF Fresno at Community Cancer Institute, Clovis, California, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Taxane-based ChemotherapyDrug: PlaceboDrug: Optional Endocrine Therapy of Investigator's Choice
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 230
- Registration Number
- NCT05894239
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇹🇷Gazi University Medical Faculty, Ankara, Turkey
🇹🇳Farhat Hached Hospital, Sousse, Tunisia
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2000
- Registration Number
- NCT05878769
- Locations
- 🇨🇿
KASMED s.r.o., Tábor, Czechia
🇩🇰Aalborg Universitetshospital, Aalborg, Denmark
🇫🇷Clinique de l'Europe, Amiens, France
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1200
- Registration Number
- NCT05872763
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳Beijing Chest Hospital, Beijing, China
🇨🇳Sichuan Provincial Cancer Hospital, Chengdu, China
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT05861986
- Locations
- 🇵🇱
Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa, Poland
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT05861999
- Locations
- 🇺🇸
Children'S Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Valley Children's Hospital, Madera, California, United States